Best Hospitals for Coronary Artery Bypass Grafting in Dubai, UAE

The total cost of CABG in India typically ranges from USD 5,000 to USD 9,000 for a standard 3-vessel bypass at a JCI or NABH-accredited hospital. This estimate generally includes the surgical procedure, cardiopulmonary bypass or off-pump equipment, 7–10 days of hospital stay (inclusive of 1–2 days in the Cardiac ICU), standard cardiac medications, and routine post-operative monitoring. More complex cases — such as CABG combined with valve replacement, robotic-assisted techniques, or procedures in patients with severely reduced ejection fraction requiring IABP support — may extend toward the upper range or beyond. In the UAE (Dubai or Abu Dhabi), the same procedure at a JCI and DHA-accredited institution ranges from approximately USD 13,000 to USD 22,000, reflecting higher facility operational costs, premium hospital infrastructure, and the higher cost of living in the region. Both destinations offer internationally benchmarked clinical outcomes. These figures do not typically include airfare, accommodation for attendants, extended outpatient follow-up visits, or additional investigations identified during pre-operative workup. GAF Healthcare provides patients with a fully itemized cost estimate before travel, with no hidden fees, based on the individual patient's coronary angiography findings and risk profile.

Patients undergoing CABG should plan for a minimum total in-country stay of 4 to 6 weeks before being medically cleared for an international long-haul flight. This timeline is important and non-negotiable for safety reasons. The hospital stay itself is typically 7–10 days for an uncomplicated case, during which chest drains are removed, the sternal wound is assessed, the patient is mobilized, and cardiac rehabilitation Phase I is initiated. After hospital discharge, patients remain under outpatient cardiac follow-up in the country for a further 3–4 weeks. Fit-to-fly clearance for a long-haul international flight is granted by the treating cardiac surgeon only when all of the following criteria are met: the sternal wound is fully healed with no evidence of infection or dehiscence; no symptomatic pleural effusion is present; the patient's cardiac rhythm is stable (no active arrhythmia requiring IV medication); the patient can walk 200 meters on a flat surface without significant breathlessness or chest pain; and all critical post-operative medications have been stabilized on oral formulations. For shorter regional flights (under 3 hours), clearance may be granted slightly earlier — typically at 3–4 weeks — subject to the above criteria. All patients traveling by air post-CABG are advised to wear graduated compression stockings, maintain adequate hydration, and ambulate every 45–60 minutes during the flight to reduce the risk of deep vein thrombosis. GAF Healthcare provides an official fit-to-fly medical certificate and a travel medical summary letter for airline and insurance purposes before the patient's departure.

The 30-day operative survival rate for elective, isolated CABG in appropriately selected patients at high-volume, internationally accredited centers in India and the UAE is 95–98%, which is statistically comparable to outcomes reported by leading cardiac surgery programs in the United States and Europe. This success rate must be contextualized carefully. The figure applies to elective CABG in patients with preserved or mildly reduced left ventricular ejection fraction (LVEF >40%), without significant comorbidities. In higher-risk patient groups — such as those with severely reduced LVEF (<30%), emergency CABG for acute MI with cardiogenic shock, concomitant valve surgery, or significant renal or pulmonary disease — operative mortality is correspondingly higher and is quantified pre-operatively using the EuroSCORE II and STS Predicted Risk of Mortality (PROM) scoring systems. Longer-term outcomes are highly favorable: freedom from major adverse cardiac events (MACE — recurrent MI, stroke, or death) at 5 years is approximately 85–90% in patients who adhere to evidence-based secondary prevention. The LIMA-to-LAD graft — the cornerstone conduit in all CABG procedures — maintains >90% patency at 10 years, which is the key driver of CABG's long-term survival advantage over drug-eluting stent PCI in multivessel and left main CAD. GAF Healthcare exclusively partners with cardiac surgery programs that maintain prospective outcomes data and are subject to external quality audits — JCI and NABH accreditation in India, and JCI and DHA accreditation in the UAE — providing patients with objective, independently verified assurance of surgical quality and safety standards.